Symphogen A/S

Autocratic, bureaucratic, charismatic, democratic. How leaders exercise power is to a large extent a function of the company’s societal context. But while societal norms and cultures differ, all leade

Servier ’s vorasedinib has shown promise in the Phase III INDIGO trial in low-grade glioma, prompting the firm to turn attention to regulatory filing and supply plans as its broader strategic focus on

Les Laboratoires Servier is on a mission to add some spark to its neuroscience pipeline by developing RNA-targeting drugs for neurodegenerative conditions as it tries to follow in the footsteps of th

Les Laboratoires Servier ’s two-pronged approach to cancer R&D, focused on immunotherapy and programmed cell death, spans both solid and liquid tumors but homes in on those diseases with a high unmet